Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2018 pp 777–791Cite as

Sexualhormone

  • Chapter

  • 2651 Accesses

Zusammenfassung

Die wichtigsten Gruppen der Sexualhormone sind Östrogenpräparate und Kontrazeptiva. Danach folgen mit weitem Abstand Androgene, Antiandrogene und Gestagene. Die Verordnungen aller Östrogenpräparate zur Hormontherapie in der Postmenopause (sytemische und topische Präparate) sind seit 2008 betrachtet um 24% zurückgegangen. Von 2016 auf 2017 zeigte sich nur noch ein minimaler weiterer Gesamtrückgang von 1% insbesondere bei Kombinationspräparaten von 4%. Damit sind die Therapieempfehlungen zur postmenopausalen Hormontherapie umgesetzt und führen zu stabilen Verordnungszahlen. Nach langjähriger Konstanz zeigten auch die hormonalen Kontrazeptiva seit 2008 eine kontinuierliche Verordnungsabnahme um 27% bis 2017 mit einer weiteren Abnahme um knapp 8% von 2016 bis 2017. Die Gestagenverordnungen haben weiterhin gering mit 7,8% zugenommen und nur noch 1,8% bei reinen Gestagenkontrazeptiva. Die Zunahme der Testosteronverordnungen ist im letzten Jahr nur noch moderat ausgefallen, hat aber seit 10 Jahren dreifach zugenommen.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American College of Obstetricians and Gynecologists (2013): Committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 121: 887–890

    Google Scholar 

  • Basaria S, Coviello AD, Travison TG, Storer TW, Farwell W R, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010): Adverse events associated with testosterone administration. N Engl J Med 363: 109–122

    Google Scholar 

  • Beral V, Doll R, Hermon C, Peto R, Reeves G (2008): Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 371: 303–314

    Google Scholar 

  • Biglia N, Carinelli S, Maiorana A, D’Alonzo M, Lo Monte G, Marci R (2014): Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther 8: 285–292

    Google Scholar 

  • Bundesminister für Gesundheit (2015): Verordnung zur Änderung der Arzneimittelverschreibungsverordnung und der Apothekenbetriebsordnung vom 6. März 2015. Bundesgesetzblatt 2015, Teil I, Nr. 10, Seite 278, ausgegeben zu Bonn am 13. März 2015

    Google Scholar 

  • Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group (2007): Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840–845

    Google Scholar 

  • Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF (2004): Interventions for emergency contraception. Cochrane Database Syst Rev. 2004; (3): CD001324

    Google Scholar 

  • Chester RC, Kling JM, Manson JE (2018): What the Women‘s Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol 41: 247–252

    Google Scholar 

  • Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators (2010): Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1684–1692

    Google Scholar 

  • Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer (2005): Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6: 552–553

    Google Scholar 

  • Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J (2006): Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 108: 1089–1097

    Google Scholar 

  • de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM (2014): Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014 Mar 3;3:CD010813. doi: 10.1002/14651858.cd010813.pub2. Review

  • Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (Hrsg) (2009): Hormontherapie in der Peri- und Postmenopause (HT), gültig bis 01.09.2014, in Überarbeitung. Internet: http://www.awmf.org/leitlinien/detail/ll/015-062.html

  • Dinger J, Assmann A, Möhner S, Minh TD (2010): Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 36: 123–129

    Google Scholar 

  • Editorial (2015): HRT for menopause: a NICE treatment? Lancet 386: 2030

    Google Scholar 

  • European Medicines Agency (2018): Esmya: new measures to minimise risk of rare but serious liver injury. EMA concludes review of medicine for uterine fibroids. Internet: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Esmya/human_referral_prac_000070.jsp&mid=WC0b01ac05805c516f

  • Food and Drug Administration (2018): FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. Internet: https://www.fda.gov/Drugs/DrugSafety/ucm436259.htm

  • Ford O, Lethaby A, Roberts H, Mol BW (2012): Progesterone for premenstrual syndrome. Cochrane Database Syst Rev. 2012 Mar 14;3:CD003415

    Google Scholar 

  • Gronich N, Lavi I, Rennert G (2011): Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 183: E1319–1325

    Google Scholar 

  • Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators (2008): Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299: 1036–1045

    Google Scholar 

  • Hickey M, Banks E (2016): NICE guidelines on the menopause. BMJ Jan 18; 352: i191

    Google Scholar 

  • Hilbert-Walter A, Büttner R, Sieber C, Bollheimer C (2013): Testosteron im Alter: ein Update. Dtsch Med Wochenschr 137: 2117–2122

    Google Scholar 

  • Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995): Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589–1593

    Google Scholar 

  • Keaney JF, Solomon CG (2016): Postmenopausal hormone therapy and atherosclerosis – Time is of the essence. N Engl J Med 374: 1279–1280

    Google Scholar 

  • Kemmeren JM, Algra A, Grobbee DE (2001): Third generation oral contraceptives and risk of venous thrombosis: metaanalysis. Brit Med J 323: 1–9

    Google Scholar 

  • LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators (2011): Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305: 1305–1314

    Google Scholar 

  • Larivée N, Suissa S, Khosrow-Khavar F, Tagalakis V, Filion KB (2017): Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies. BJOG Mar 9. doi: 10.1111/1471-0528.14623. [Epub ahead of print]

  • Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (2011): Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 25;343:d6423

    Google Scholar 

  • Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E (2013): Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 344: e2990

    Google Scholar 

  • Løkkegaard ECL, Mørch LS (2018): Tibolone and risk of gynecological hormone sensitive cancer. Int J Cancer 142: 2435–2440

    Google Scholar 

  • Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM (2006): A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 13: 737–743

    Google Scholar 

  • Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O‘Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013): Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women‘s Health Initiative randomized trials. JAMA 310: 1353–1368

    Google Scholar 

  • McFadyen IJ, Forrest APM, Raab GM, Macintyre CCA (1989): Progesterone cream for cyclic breast pain. Brit Med J 289: 931

    Google Scholar 

  • Million Women Study Collaborators (2003): Breast cancer and hormone-replacement in the Million Women Study. Lancet 362: 419–427

    Google Scholar 

  • Modelska K, Cummings S (2002): Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87:16–23

    Google Scholar 

  • National Institute for Health and Care Excellence (2015): Menopause: diagnosis and management. NICE guideline published 12 November 2015 (NG 23). Internet: https://www.nice.org.uk/guidance/ng23

  • Nelson HD (2004): Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291: 1610–1620

    Google Scholar 

  • Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO (2005): Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71: 176–182

    Google Scholar 

  • Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM (2015): Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015 Aug 27;(8):CD011054

    Google Scholar 

  • Rote-Hand-Brief (2014): Kombinierte hormonale Kontrazeptiva: Unterschiede hinsichtlich des Thromboembolie-Risikos unterschiedlicher Präparate. Internet: https://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2014/20140130.pdf

  • Royal College of General Practitioners Oral Contraception Study (1981): Further analysis of mortality in oral contraceptive users. Lancet I: 541–546

    Google Scholar 

  • Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004): Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89: 5429–5434

    Google Scholar 

  • Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996): Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit Med J 312: 83–88

    Google Scholar 

  • Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ (2015): Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100: 3975–4011

    Google Scholar 

  • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995): Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588

    Google Scholar 

  • Womens Health Initiative Steering Committee (2004): Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291: 1701–1712

    Google Scholar 

  • Writing Group for the Women’s Health Initiative Investigators (2002): Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333

    Google Scholar 

  • Wu C, Grandi S, Filion K, Abenhaim H, Joseph L, Eisenberg M (2013): Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review. BJOG 120: 801–811

    Google Scholar 

  • Yang LP, Plosker GL (2012): Nomegestrol acetate/estradiol: in oral contraception. Drugs 72: 1917–1928

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Frauenklinik Gynäkologische Endokrinologie und Fertilitätsstörungen, Neuenheimer Feld 440, 69120, Heidelberg, Deutschland

    Thomas Strowitzki

Authors
  1. Thomas Strowitzki
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Deutschland

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178, Berlin, Deutschland

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Cite this chapter

Strowitzki, T. (2018). Sexualhormone. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2018. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57386-0_44

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57386-0_44

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57385-3

  • Online ISBN: 978-3-662-57386-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation